Benzinga · Feb 6, 2026
Guggenheim Maintains Buy on Nanobiotix, Raises Price Target to $26
Guggenheim analyst Michael Schmidt maintains Nanobiotix (NASDAQ:NBTX) with a Buy and raises the price target from $8 to $26.
NB
NASDAQ · NBTX
Nanobiotix S.A. American Depositary Shares
Healthcare · Biotechnology
$25.23
Up+$0.13 (+0.52%)
Updated Oct 7, 2026, 3:45 AM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.11B
- P/E ratio
- -13.81
- Dividend yield
- 0.00%
- 52-week range
- $14.78 – $57.14
- Volume
- 156.3K
- Avg. volume
- 101.98K
Price performance · NBTX
NBTX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
NBTX closed at $25.23 after 21 trading sessions, down 33.94% for the selected period.
- Last close
- $25.23
- Period change
- -33.94%
- Period low
- $25.10
- Period high
- $38.19
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $25.69 | $25.69 | $24.16 | $25.23 | 156.3K |
| Oct 5, 2026 | $25.77 | $25.97 | $24.24 | $25.10 | 194.24K |
| Oct 2, 2026 | $27.39 | $27.425 | $25.23 | $25.75 | 255.77K |
| Oct 1, 2026 | $29.99 | $30.36 | $27.28 | $27.90 | 192.41K |
| Sep 30, 2026 | $31.73 | $32.895 | $31.16 | $31.16 | 311.37K |
| Sep 29, 2026 | $32.47 | $32.47 | $31.07 | $31.50 | 163.48K |
| Sep 28, 2026 | $32.47 | $34.00 | $31.69 | $32.60 | 49.38K |
| Sep 25, 2026 | $32.57 | $34.06 | $32.25 | $33.31 | 124.58K |
| Sep 24, 2026 | $33.45 | $34.65 | $31.57 | $33.46 | 203.17K |
| Sep 23, 2026 | $36.05 | $36.10 | $34.73 | $35.24 | 126.95K |
| Sep 22, 2026 | $34.65 | $35.7999 | $34.07 | $35.15 | 44.02K |
| Sep 21, 2026 | $33.57 | $34.7906 | $33.045 | $34.50 | 94.53K |
| Sep 18, 2026 | $34.89 | $35.60 | $33.01 | $33.05 | 149.34K |
| Sep 17, 2026 | $34.63 | $35.96 | $34.63 | $35.88 | 99.77K |
| Sep 16, 2026 | $34.64 | $35.34 | $33.80 | $34.40 | 198.7K |
| Sep 15, 2026 | $36.06 | $36.995 | $35.25 | $35.26 | 135.75K |
| Sep 14, 2026 | $36.00 | $36.885 | $34.885 | $35.73 | 128.51K |
| Sep 11, 2026 | $37.00 | $37.70 | $36.43 | $37.01 | 93.82K |
| Sep 10, 2026 | $36.99 | $38.81 | $36.615 | $37.60 | 200.14K |
| Sep 9, 2026 | $35.45 | $36.72 | $35.45 | $36.64 | 106.47K |
| Sep 8, 2026 | $37.94 | $39.15 | $37.48 | $38.19 | 102.9K |
Latest NBTX news
The latest Smart Investors Daily articles mentioning NBTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NBTX research
Overview
Company profile and research snapshot.
Company profile
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $26.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | ODDO BHF | Buy | — |
| Sep 14, 2026 | JEFFERIES | Buy | — |
| Sep 14, 2026 | STIFEL EUROPE | Buy | — |
| Jun 3, 2026 | ODDO BHF | Buy | — |
| Jun 3, 2026 | STIFEL EUROPE | Buy | — |
News briefing
No generated briefing is available yet.
globenewswire.com · Nov 24, 2025
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
PARIS and CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today reported an operational update and financial results for the third quarter of 2025 along with an outlook for clinical updates from studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center (“MD Anderson”) expected in 2026 and announced the closing of its non-dilutive royalty financing transaction with HCRx.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
